Search

Axsome Therapeutics Inc

Закрыт

СекторЗдравоохранение

207.46 0.81

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

200.92

Макс.

210.12

Ключевые показатели

By Trading Economics

Доход

13M

-51M

Продажи

27M

218M

Прибыль на акцию

-0.99

Рентабельность продаж

-23.498

Сотрудники

1,346

EBITDA

11M

-50M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+40.8% upside

Дивиденды

By Acuity

Следующий отчет о доходах

2 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-34M

11B

Предыдущая цена открытия

206.65

Предыдущая цена закрытия

207.46

Новостные настроения

By Acuity

49%

51%

131 / 339 Рейтинг в Healthcare

Axsome Therapeutics Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 сент. 2026 г., 19:36 UTC

Axsome Therapeutics Inc shares are higher today amid routine trading, with no specific company news identified. The stock has gained since Friday's close.

4 сент. 2026 г., 22:40 UTC

Axsome Therapeutics Inc. shares are higher in after-market hours, recovering from an earlier pullback and achieving a notable return since Friday's close.

3 сент. 2026 г., 20:07 UTC

Axsome Therapeutics Inc shares are trading lower today, with no specific news identified to explain the decline amid a broader market downturn.

2 сент. 2026 г., 20:01 UTC

News

Axsome Therapeutics will participate in several upcoming investor conferences, boosting shares amid positive sentiment regarding its outreach efforts.

1 сент. 2026 г., 19:51 UTC

Event
News

Axsome Therapeutics Inc. announced the first patient has been dosed in the SUMMIT Phase 3 trial of AXS-05 for smoking cessation, boosting shares higher.

31 авг. 2026 г., 21:02 UTC

Event

Axsome Therapeutics shares rise in after-market hours following the dosing of the first patient in the SUMMIT Phase 3 trial for AXS-05.

29 авг. 2026 г., 00:01 UTC

Axsome Therapeutics Inc is higher in after-market trading, advancing since Friday's close, though still below its 20-day moving average.

28 авг. 2026 г., 23:46 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, though no specific news was identified to explain the movement. They remain below their 20-day moving average.

27 авг. 2026 г., 19:36 UTC

Axsome Therapeutics Inc. shares are trading lower, continuing a decline since Wednesday and remaining near the lower end of their one-month trading range.

26 авг. 2026 г., 19:36 UTC

Axsome Therapeutics Inc. shares are trading higher today, recovering from an early dip. The stock remains below its 20-day moving average.

25 авг. 2026 г., 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a trend of four consecutive sessions finishing down and trading below the 20-day moving average.

24 авг. 2026 г., 21:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading. The stock has declined for four consecutive sessions and remains below its 20-day moving average.

21 авг. 2026 г., 19:41 UTC

Axsome Therapeutics Inc. shares are lower today, retracing from earlier gains and remaining below the 20-day moving average amid rising Treasury yields.

20 авг. 2026 г., 20:01 UTC

Axsome Therapeutics Inc's shares are declining amid broader market pressures from Walmart's disappointing earnings, raising concerns about consumer spending.

17 авг. 2026 г., 19:16 UTC

Axsome Therapeutics Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

14 авг. 2026 г., 19:36 UTC

Axsome Therapeutics Inc shares are higher today, rebounding from an earlier pullback, despite a broader market influenced by a decline in retail sales.

13 авг. 2026 г., 19:56 UTC

Axsome Therapeutics Inc shares are declining, retracing from earlier session highs amid broader market trends and rising U.S. unemployment claims.

12 авг. 2026 г., 22:36 UTC

Axsome Therapeutics shares higher in after-market trading, with no specific news identified. Broader market stability follows recent inflation data easing rate hike concerns.

11 авг. 2026 г., 19:45 UTC

Social Media
News

Axsome Therapeutics shares are lower following a second-quarter loss of 99 cents per share, missing the consensus estimate of 83 cents.

10 авг. 2026 г., 23:06 UTC

Axsome Therapeutics Inc shares are lower during after-market hours amid mixed market sentiment. The stock is trading below its 20-day moving average.

7 авг. 2026 г., 19:52 UTC

Axsome Therapeutics Inc shares are higher during Friday's session, recovering from a brief dip after reaching a session high. No specific news was identified.

6 авг. 2026 г., 23:01 UTC

Axsome Therapeutics Inc. is trading higher in after-market hours, showing stability despite no specific news. The stock remains below its 20-day moving average.

5 авг. 2026 г., 19:36 UTC

Axsome Therapeutics Inc shares are lower, pulling back from earlier session highs. The stock remains significantly below its 20-day moving average.

4 авг. 2026 г., 23:36 UTC

Axsome Therapeutics Inc shares are trading higher in after-market hours. Broader market dynamics may be influencing sentiment amid record highs in stock markets.

3 авг. 2026 г., 22:16 UTC

Axsome Therapeutics Inc shares are higher in after-market hours, despite no specific news. The stock showed unusual activity amid broader market dynamics.

31 июл. 2026 г., 22:01 UTC

Axsome Therapeutics Inc shares are higher in after-market trading, reflecting strong interest despite no specific news. The stock remains below its 20-day moving average.

30 июл. 2026 г., 19:28 UTC

Axsome Therapeutics Inc is rising during Thursday's session, reversing four consecutive lower closes. The stock remains below its 20-day moving average.

29 июл. 2026 г., 22:01 UTC

Axsome Therapeutics Inc shares are lower in after-market trading, closing below their 20-day moving average amid broader market caution and geopolitical tensions.

28 июл. 2026 г., 19:51 UTC

Axsome Therapeutics Inc shares are lower today, breaking a trend of higher daily closes amid broader market declines, particularly in Asian markets.

27 июл. 2026 г., 20:14 UTC

Axsome Therapeutics Inc shares are lower in after-market hours, continuing a three-session trend. No specific news was identified to explain the movement.

Сравнение c конкурентами

Изменение цены

Axsome Therapeutics Inc Прогноз

Целевая цена

By TipRanks

40.8% рост

Прогноз на 12 месяцев

Средняя 291 USD  40.8%

Максимум 380 USD

Минимум 251 USD

Основано на мнении 13 аналитиков Wall Street, спрогнозировавших целевые цены для Axsome Therapeutics Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

13 ratings

12

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

131 / 339Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
help-icon Live chat